Molecular mechanisms of angiostasis

Encyclopedia of the Eye, Four-Volume Set

Volumn , Issue , 2010, Pages 52-59

  Sudhakar, A ^a   Kalluri, R ^b,c  

^a BOYS TOWN NATIONAL RESEARCH HOSPITAL   (United States)

^b Department of Medicine ^*  (Israel)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Arresten ( 1(IV)NC1); Basic fibroblast growth factor (bFGF); Canstatin ( 2(IV)NC1); Matrix metalloproteinase (MMP); Tumstatin ( 3(IV)NC1); Vascular basement membrane (VBM); Vascular endothelial cell growth factor (VEGF); 6(IV)NC1

Indexed keywords

EID: 84893051738     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374203-2.00128-7     Document Type: Chapter

References (17)

1. C.S. Boosani., A.P. Mannam., D. Cosgrove., et al. Regulation of COX-2 mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis Blood Journal 110 2007 1168-1177.
2. J. Folkman., R. Kalluri Tumor Angiogenesis. Part II Scientific Foundation, Section 1: Cancer Biology. Cancer Medicine 6th edn. 2002 BC Decker London.
3. Y. Hamano., M. Zeisberg., H. Sugimoto., et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin Cancer Cell 3 2003 589-601.
4. R. Kalluri Discovery of type IV collagen non-collagenous domains as novel integrin ligands and endogenous inhibitors of angiogenesis Cold Spring Harbor Symposia on Quantitative Biology 67 2002 255-266.
5. R. Kalluri Basement membranes: Structure, assembly and role in tumour angiogenesis Nature Reviews Cancer 3 2003 422-433.
6. Y. Maeshima., P.C. Colorado., A. Torre., et al. Distinct anti-tumor properties of a type IV collagen domain derived from basement membrane Journal of Biological Chemistry 275 2000 21340-21348.
7. Y. Maeshima., A. Sudhakar., J.C. Lively., et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis Science 295 2002 140-143.
8. C. Magnon., A. Galaup., B. Mullan., et al. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with αVβ3 and αVβ5 integrins Cancer Research 65 2005 4353-4361.
9. T.M. Mundel., A.M. Yliniemi., Y. Maeshima., et al. Type IV collagen alpha6 chain-derived noncollagenous domain 1 (α6(IV)NC1) inhibits angiogenesis and tumor growth International Journal of Cancer 122 2008 1738-1744.
10. P. Nyberg., L. Xie., R. Kalluri Endogenous inhibitors of angiogenesis Cancer Research 65 2005 3967-3979.
11. P. Nyberg., L. Xie., H. Sugimoto., et al. Characterization of the anti-angiogenic properties of arresten, an alpha1beta1 integrin-dependent collagen-derived tumor suppressor Experimental Cell Research 314 18 2008 3292-3305.
12. E. Petitclerc., A. Boutaud., A. Prestayko., et al. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo Journal of Biological Chemistry 275 2000 8051-8061.
13. R.L.E. Silva., S. Kachi., H. Akiyama., et al. Recombinant non-collagenous domain of α2(IV) collagen causes involution of choroidal neovascularization by inducing apoptosis Journal of Cellular Physiology 208 2006 161-166.
14. A. Sudhakar., C.S. Boosani Signaling mechanisms of endogenous angiogenesis inhibitors derived from type IV collagen Gene Regulation and System Biology 1 2007 217-226.
15. A. Sudhakar., C.S. Boosani Inhibition of tumor angiogenesis by tumstatin: Insights into signaling mechanisms and implications in cancer regression Pharmaceutical Research 12 2008 2731-2739.
16. A. Sudhakar., P. Nyberg., V.G. Keshamouni., et al. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin Journal of Clinical Investigation 115 2005 2801-2810.
17. X. Zhang., B.G. Hudson., M.P. Sarras Jr. Hydra cell aggregate development is blocked by selective fragment of fibronectin and type IV collagen Developmental Biology 164 1994 10-23.